HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for ...
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross ...
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ -- ...
Add Yahoo as a preferred source to see more of our stories on Google. PRKAG2 syndrome is an autosomal dominant Atrium Therapeutics has received clearance from the US Food and Drug Administration (FDA) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A phase 2/3 randomized, double-masked, ...
Orexo AB (publ.) today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OX640, a nasally administered powder formulation of ...
MALVERN, Pa.--(BUSINESS WIRE)--NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today ...
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results